Frontiers in Psychiatry
February 1, 2024
Alessandro Rodolico, Pierfelice Cutrufelli, Antonio Di Francesco et al.
28 citations
Background Unipolar and bipolar depression present treatment challenges, with patients sometimes showing limited or no response to standard medications. Ketamine and its enantiomer, esketamine, offer promising alternative treatments that can quickly relieve suicidal thoughts. This Overview of Reviews (OoR) analyzed and synthesized systematic reviews (SRs) with meta-analysis on randomized...
Australian & New Zealand Journal of Psychiatry
February 1, 2024
Anthony Rodgers, Dilara Bahceci, Christopher G. Davey et al.
8 citations
In this paper, the case study of ketamine as a new treatment for severe depression is used to outline the challenges of repurposing established medicines and we suggest potential solutions. The antidepressant effects of generic racemic ketamine were identified over 20 years ago, but there were insufficient incentives for commercial entities to pursue its registration, or support for...
Cureus
February 1, 2024
Suneeta Kumari, Hassan A Chaudhry, Adam Sagot et al.
13 citations
The expansive spectrum of major depressive disorder (MDD) continues to pose challenges for psychiatrists to treat effectively. Oral antidepressant (OAD) medications that alter monoamine neurotransmitters, mainly selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs), have been the mainstay of therapy for decades. Although these drugs have been...
International Clinical Psychopharmacology
January 22, 2024
L. Chevalier, Samuel Bulteau, L. Cheval et al.
Intranasal esketamine is used in France for treatment-resistant depression. Dissociative symptoms are common side effects during treatment sessions. We report a case of delayed spontaneous dissociative symptoms following esketamine administration. A 20-year-old female with treatment-resistant depression received esketamine treatment. Dissociative symptoms occurred during sessions and persisted...
January 18, 2024
Esketamine has shown enhancements in processing speed, working memory, and verbal learning in adolescents with major depressive disorder and suicidal ideation. More studies are needed to determine esketamine dosing, its long-term side effects, and clinical benefits.
Journal of Affective Disorders
2024
Shu-Ying Li, Wen-Qin Zhou, Ping Li et al.
BACKGROUND Ketamine and esketamine has been suggested to have potential efficacy in preventing postpartum depression (PPD) recent years. The aim of this meta-analysis was to evaluate the effectiveness of ketamine and esketamine on PPD after cesarean delivery. METHODS We systematically searched PubMed, Embase, and the Cochrane Library for studies investigating the efficacy of ketamine and...
The Brown University Psychopharmacology Update
2024
A Phase 3b open‐label trial has found that esketamine nasal spray in combination with an antidepressant was more efficacious than extended‐release quetiapine plus an antidepressant in patients with treatment‐resistant depression. Both patient groups experienced improved remission rates over time.
Journal of Affective Disorders
2024
Liliana Patarroyo-Rodriguez, Vanessa M. Pazdernik, Jennifer L. Vande Voort et al.
12 citations
BACKGROUND Sleep disturbances are highly prevalent in depressive episodes and are linked to higher mood severity and suicidal behaviors. Slow wave sleep (SWS) and REM sleep are compromised in depression. Current evidence suggests that rapid antidepressant effects of intravenous (IV) ketamine in patients with treatment-resistant depression (TRD) is mediated by its effects on SWS and REM sleep....
Journal of Psychoactive Drugs
2024
Julia M.k. Freind, Fernando R. Beserra, Bruno S Menezes et al.
9 citations
Depression is one of the most prevalent mental health disorders globally, causing severe emotional suffering, reducing life expectancy and increasing the risk of suicide. Recently, the use of dissociative psychedelic substances such as ketamine and esketamine for depressive disorders has expanded treatment options. We sought to analyze, through a systematic review, the existing protocols for...
Frontiers in Psychiatry
2024
Alexandros Matsingos, Marcel Wilhelm, Laila Noor et al.
18 citations
Ketamine and esketamine offer a novel approach in the pharmacological treatment of major depressive disorder (MDD). This meta-analysis aimed to investigate the placebo response in double-blind, randomized controlled studies (RCTs) on patients with MDD receiving ketamine or esketamine. For this systematic review and meta-analysis Medline (PubMed), Cochrane Central Register of Controlled Trials...